On November 28, at the seminar jointly organized by the National Cancer Center and ARCALIS titled “Current Status and Challenges in mRNA Vaccine Development”, Mr. Kazuyuki Nakashima, General Manager of ARCALIS Development department, will deliver a lecture.

Seminar Details
Date & Time: Friday, November 28, 2025, 5PM0–6PM
Venue: Nihonbashi Life Science Building, Room 313, 2-3-11 Nihonbashi-Honcho, Chuo-ku, Tokyo
Speaker: Kazuyuki Nakashima, General Manager, ARCALIS Development Department
Lecture Title: Quality Strategy for mRNA therapeutics and Vaccine Development

Presentation Abstract:
The manufacture of mRNA therapeutics with high efficacy and safety involves multiple critical factors. First, the efficacy of mRNA therapeutics depends on robust expression of the target protein, which can be achieved through codon optimization of the coding sequence (CDS) and the use of expression-enhancing systems such as self-amplifying RNA. Second, ensuring safety requires minimizing impurities such as double-stranded RNA (dsRNA). Furthermore, the development of new analytical methods has revealed additional quality attributes that must be considered in relation to efficacy and safety. In this presentation, we will introduce quality strategies tailored to the manufacturing process for producing ideal mRNA therapeutics with superior safety and efficacy, highlighting our recent achievements.